Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Messenger RNAs (mRNAs) bearing miR-148a-5p seed-complementary sites represent the collective group of transcripts post-transcriptionally regulated by the microRNA miR-148a-5p. These mRNAs contain specific sequences, typically in their 3' untranslated regions (UTRs), that pair with the 5' 'seed' region of the miRNA, facilitating binding by the RNA-induced silencing complex (RISC) (PMID: 21454424). This interaction leads to gene silencing through either mRNA degradation or the inhibition of protein translation. miR-148a-5p is a critical regulator of diverse biological processes, including DNA methylation via its targeting of DNMT1 and apoptosis via BCL2 (PMID: 24607418). In various malignancies, such as hepatocellular and gastric carcinomas, miR-148a-5p often acts as a tumor suppressor; its downregulation leads to the pathological overexpression of these target mRNAs, promoting cell proliferation and metastasis (PMID: 24333734). Therapeutic intervention typically involves the use of miRNA mimics to restore the silencing of these mRNAs or antagomirs to inhibit miRNA activity in specific disease contexts. However, because a single miRNA can regulate hundreds of different mRNAs simultaneously, achieving high therapeutic specificity without off-target effects remains a significant challenge in drug development (PMID: 23873015).
miRNA mimics bind to these mRNA sites to induce translational repression or mRNA cleavage via the RISC complex, while antagomirs prevent endogenous miRNA binding to de-repress the target mRNAs.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Messenger RNAs bearing miR-148a-5p seed-complementary sites (miR-148a-5p targets).